File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting papain-like protease for broad-spectrum coronavirus inhibition

TitleTargeting papain-like protease for broad-spectrum coronavirus inhibition
Authors
Keywordsantiviral
coronavirus
inhibitor
Nsp3
protease
Issue Date2022
Citation
Protein and Cell, 2022, v. 13, n. 12, p. 940-953 How to Cite?
AbstractThe emergence of SARS-CoV-2 variants of concern and repeated outbreaks of coronavirus epidemics in the past two decades emphasize the need for next-generation pan-coronaviral therapeutics. Drugging the multi-functional papain-like protease (PLpro) domain of the viral nsp3 holds promise. However, none of the known coronavirus PLpro inhibitors has been shown to be in vivo active. Herein, we screened a structurally diverse library of 50,080 compounds for potential coronavirus PLpro inhibitors and identified a noncovalent lead inhibitor F0213 that has broad-spectrum anti-coronaviral activity, including against the Sarbecoviruses (SARS-CoV-1 and SARS-CoV-2), Merbecovirus (MERS-CoV), as well as the Alphacoronavirus (hCoV-229E and hCoV-OC43). Importantly, F0213 confers protection in both SARS-CoV-2-infected hamsters and MERS-CoV-infected human DPP4-knockin mice. F0213 possesses a dual therapeutic functionality that suppresses coronavirus replication via blocking viral polyprotein cleavage, as well as promoting antiviral immunity by antagonizing the PLpro deubiquitinase activity. Despite the significant difference of substrate recognition, mode of inhibition studies suggest that F0213 is a competitive inhibitor against SARS2-PLpro via binding with the 157K amino acid residue, whereas an allosteric inhibitor of MERS-PLpro interacting with its 271E position. Our proof-of-concept findings demonstrated that PLpro is a valid target for the development of broad-spectrum anti-coronavirus agents. The orally administered F0213 may serve as a promising lead compound for combating the ongoing COVID-19 pandemic and future coronavirus outbreaks.
Persistent Identifierhttp://hdl.handle.net/10722/315392
ISSN
2023 Impact Factor: 13.6
2023 SCImago Journal Rankings: 4.412
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYuan, Shuofeng-
dc.contributor.authorGao, Xiaopan-
dc.contributor.authorTang, Kaiming-
dc.contributor.authorCai, Jian Piao-
dc.contributor.authorHu, Menglong-
dc.contributor.authorLuo, Peng-
dc.contributor.authorWen, Lei-
dc.contributor.authorYe, Zi Wei-
dc.contributor.authorLuo, Cuiting-
dc.contributor.authorTsang, Jessica Oi Ling-
dc.contributor.authorChan, Chris Chun Yiu-
dc.contributor.authorHuang, Yaoqiang-
dc.contributor.authorCao, Jianli-
dc.contributor.authorLiang, Ronghui-
dc.contributor.authorQin, Zhenzhi-
dc.contributor.authorQin, Bo-
dc.contributor.authorYin, Feifei-
dc.contributor.authorChu, Hin-
dc.contributor.authorJin, Dong Yan-
dc.contributor.authorSun, Ren-
dc.contributor.authorChan, Jasper Fuk Woo-
dc.contributor.authorCui, Sheng-
dc.contributor.authorYuen, Kwok Yung-
dc.date.accessioned2022-08-05T10:18:43Z-
dc.date.available2022-08-05T10:18:43Z-
dc.date.issued2022-
dc.identifier.citationProtein and Cell, 2022, v. 13, n. 12, p. 940-953-
dc.identifier.issn1674-800X-
dc.identifier.urihttp://hdl.handle.net/10722/315392-
dc.description.abstractThe emergence of SARS-CoV-2 variants of concern and repeated outbreaks of coronavirus epidemics in the past two decades emphasize the need for next-generation pan-coronaviral therapeutics. Drugging the multi-functional papain-like protease (PLpro) domain of the viral nsp3 holds promise. However, none of the known coronavirus PLpro inhibitors has been shown to be in vivo active. Herein, we screened a structurally diverse library of 50,080 compounds for potential coronavirus PLpro inhibitors and identified a noncovalent lead inhibitor F0213 that has broad-spectrum anti-coronaviral activity, including against the Sarbecoviruses (SARS-CoV-1 and SARS-CoV-2), Merbecovirus (MERS-CoV), as well as the Alphacoronavirus (hCoV-229E and hCoV-OC43). Importantly, F0213 confers protection in both SARS-CoV-2-infected hamsters and MERS-CoV-infected human DPP4-knockin mice. F0213 possesses a dual therapeutic functionality that suppresses coronavirus replication via blocking viral polyprotein cleavage, as well as promoting antiviral immunity by antagonizing the PLpro deubiquitinase activity. Despite the significant difference of substrate recognition, mode of inhibition studies suggest that F0213 is a competitive inhibitor against SARS2-PLpro via binding with the 157K amino acid residue, whereas an allosteric inhibitor of MERS-PLpro interacting with its 271E position. Our proof-of-concept findings demonstrated that PLpro is a valid target for the development of broad-spectrum anti-coronavirus agents. The orally administered F0213 may serve as a promising lead compound for combating the ongoing COVID-19 pandemic and future coronavirus outbreaks.-
dc.languageeng-
dc.relation.ispartofProtein and Cell-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectantiviral-
dc.subjectcoronavirus-
dc.subjectinhibitor-
dc.subjectNsp3-
dc.subjectprotease-
dc.titleTargeting papain-like protease for broad-spectrum coronavirus inhibition-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s13238-022-00909-3-
dc.identifier.pmid35384604-
dc.identifier.pmcidPMC8983325-
dc.identifier.scopuseid_2-s2.0-85127609643-
dc.identifier.volume13-
dc.identifier.issue12-
dc.identifier.spage940-
dc.identifier.epage953-
dc.identifier.eissn1674-8018-
dc.identifier.isiWOS:000781261200003-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats